Epidemiology of Kaposi's sarcoma-associated herpesvirus in HIV-1-infected US persons in the era of combination antiretroviral therapy.

ABSTRACT:

Objective

To determine the effect of the introduction of combination antiretroviral treatment (cART) in the HIV-1-infected US population on the epidemiology of Kaposi's sarcoma-associated herpesvirus (KSHV).

Design, setting and participants

We investigated the epidemiology of KSHV in 5022 HIV-1-infected, antiretroviral-naive US persons participating in six AIDS Clinical Trials Group (ACTG)-randomized clinical trials, and followed in a long-term cohort study. We tested the first and last available sera of each participant for antibodies to KSHV K8.1 and ORF73.

Main outcome measures

We studied prevalence and incidence of KSHV infection, incidence of Kaposi's sarcoma, and overall survival.

Results

KSHV prevalence was 38.1% [95% confidence interval (CI) 36.8-39.5%]

SUBMITTER: Labo N 

PROVIDER: S-EPMC6680245 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature